SHAREHOLDER ALERT: ACB ZSAN HPQ: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / December 1, 2020 /The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Aurora Cannabis Inc. (NYSE:ACB)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/aurora-cannabis-inc-loss-submission-form-2?prid=11299&wire=1
Lead Plaintiff Deadline: December 1, 2020
Class Period: February 13, 2020 - September 4, 2020
Allegations against ACB include that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Zosano Pharma Corporation (NASDAQ:ZSAN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11299&wire=1
Lead Plaintiff Deadline: December 28, 2020
Class Period: February 13, 2017 - September 30, 2020
Allegations against ZSAN include that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
HP Inc. (NYSE:HPQ)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hp-inc-loss-submission-form-2?prid=11299&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: November 6, 2015 - June 21, 2016
Allegations against HPQ include that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE:The Law Offices of Vincent Wong
View source version on accesswire.com:
© 2020 Accesswire. All Rights Reserved.